Dr. Morin heads the operation of the GSC/BC Cancer Proteomics Platform which uses state-of-the-art mass spectrometry instrumentation housed in the Mass Spectrometry Instrument Suite. The Platform staff and Dr. Morin collaborate with more than 40 BC Cancer, local, and non-local cancer researchers to study the mechanistic and functional roles of proteins implicated in a wide variety of cancers. These projects use global and targeted proteomic techniques integrated with genomic methods, such as RNA-seq and ChIP-seq in cancer cell lines, isogenic cell line models, and murine model systems to study aberrant protein function in multiple cancer types. The Platform has developed an ultrasensitive global proteome profiling method for the analysis of very small amounts of formalin-fixed paraffin-embedded (FFPE) clinical tumour samples. This protocol is being widely used to identify histotype specific biological processes and proteins to find candidate biomarkers and therapeutically targetable proteins and pathways.